In patients with human epidermal growth factor receptor 2 (HER2) overexpressed breast cancer, PIK3CA mutations and PTEN loss have been reported to cause activation of the downstream PI3K / Akt pathway associated with drug resistance [5, 7]. Here, ERBB2 is linked to breast cancer.